JNNP

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
[Advanced]

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Minnerop, M
Right arrow Articles by Reinhardt, M J
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Minnerop, M
Right arrow Articles by Reinhardt, M J
Journal of Neurology Neurosurgery and Psychiatry 2005;76:118-120
© 2005 BMJ Publishing Group Ltd


SHORT REPORT

Dopamine transporter SPECT in patients with mitochondrial disorders

M Minnerop1, C Kornblum1, A Y Joe2, K Tatsch4, W S Kunz3, T Klockgether1, U Wüllner1, M J Reinhardt2

1 Department of Neurology, University of Bonn, Bonn, Germany
2 Department of Nuclear Medicine, University of Bonn
3 Department of Epileptology, University of Bonn
4 Department of Nuclear Medicine, University of Munich, Munich, Germany

Correspondence to:
Correspondence to:
Dr Ullrich Wüllner
Department of Neurology, University of Bonn, Sigmund-Freud-Strasse 25, Bonn 53105, Germany; wuellner{at}uni-bonn.de


ABSTRACT
Background: Mitochondrial disorders may affect basal ganglia function. In addition, decreased activity of complex I of the mitochondrial electron transport chain has been linked to the pathogenesis of dopaminergic cell loss in Parkinson’s disease.

Objective : To investigate the dopaminergic system in patients with known mitochondrial disorders and complex I deficiency.

Methods: Dopamine transporter density was studied in 10 female patients with mitochondrial complex I deficiency by 123I-FP-CIT (N-ß-fluoropropyl-2ß-carbomethyl-3ß-(4-iodophenyl)-nortropane) SPECT.

Results: No differences in 123I-FP-CIT striatal binding ratios were observed and no correlation of the degree of complex I deficiency and striatal binding ratios could be detected.

Conclusions: These data argue against the possibility that mitochondrial complex I deficiency by itself is sufficient to elicit dopaminergic cell loss.


Abbreviations: CPEO, chronic progressive external ophthalmoplegia; DAT, dopamine transporter; SPECT, single photon emission computed tomography

Keywords: dopamine; 123 I-FP-CIT SPECT; mitochondrial disorders







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2005 by the BMJ Publishing Group Ltd.